Heterogeneity of treatment regimens and related health resource use in managing patients with waiha: A US multi-database retrospective observational Study
Retrospective study reveals high healthcare resource use in managing warm autoimmune hemolytic anemia, indicating treatment gaps persist with rituximab.
Key Points
Blood transfusion use increased from 9% to 32.8% post-rituximab, highlighting treatment needs.
Among 2,028 wAIHA patients, 55% had secondary wAIHA, with 64% receiving oral corticosteroids.
Hospitalization rate stood at 35%, with an average stay of 3.8 days, indicating healthcare resource challenges.
Rituximab, administered for wAIHA, had variable dosing practices, suggesting a need for standardized guidelines.